One of the biggest ever FSGS clinical trial run by Travere called DUPLEX (close to 400 patients in a freaking Orphan indication) study was comparing Sparsentan to an ARB.
The first fully drug approved for IgAN is called TARPEYO, the trial design was 1) Trapeyo + RASi 2) Placebo + RASi
And now you are telling us all this nonsense about ARB and role DMX-200 can play in this FSGS space..
Come up with another lie now...This one is becoming too boring..
One of the biggest ever FSGS clinical trial run by Travere...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
0.025(7.46%) |
Mkt cap ! $197.8M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.3¢ | 33.5¢ | $3.801M | 10.73M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 378856 | 6 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
36.0¢ |
Change
0.025 ( 7.33 %) |
||||
| Open | High | Low | Volume | ||
| 33.5¢ | 36.5¢ | 33.5¢ | 5557634 | ||
| Last updated 15.58pm 03/05/2024 ? | |||||
| DXB (ASX) Chart |